Browse articles from EyeWorld.org on the topic of the cornea. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ 510(k) clearance granted to pattern scanning laser indirect ophthalmoscope ➤ 12-week safety, efficacy results for wet AMD therapy ➤ Phase 3 trial for dry eye treatment complete ➤ Corneal implant company moves toward PMA submission ➤ Update on neuropathic corneal pain trial ➤ ASCRS news and events
➤ Positive topline data in Phase 1/2 allogenic cell therapy trial ➤ Investigational, light-based treatment for infectious keratitis ➤ Topline results from Phase 3 clinical trial for chronic thyroid eye disease ➤ Primary endpoint met in trial investigating extended dosing interval for retinal vein occlusion treatment ➤ Rare Pediatric Disease Designation granted to investigational retina gene therapy ➤ Merger and acquisition news ➤ ASCRS news and events
Many patients use drops to help with a variety of ophthalmic issues, however, one thing to consider is the formulation of these products, specifically if they have preservatives. Three ophthalmologists discussed the precautions with preservatives and shared the importance of monitoring for toxicity and potentially finding alternative treatment options.
In December 2020, the FDA issued “Dry Eye: Developing Drugs for Treatment Guidance for Industry” as a draft for public comment. William Boyd, MD, Deputy Division Director with the FDA’s Center for Drug Evaluation and Research, shared with EyeWorld that the administration hopes to issue its final guidance soon.
Corneal cell therapy is being investigated as a new approach for patients in need of corneal transplantation and treatment for corneal diseases. EyeWorld spoke to several physicians who have experience in this area to hear about specific approaches being developed, current status and results, and the future of these options.
Julie Schallhorn, MD, shared the topics covered in the Cornea section, specifically noting that while she is excited for cultured endothelial cell therapies, she will “remember the ingenuity that went into the development of endothelial keratoplasty and the supreme teaching and innovation that made it a procedure adopted worldwide.”
➤ Topline results for non-steroidal immunomodulator for postop inflammation ➤ Pilot study describes use of prosthetic device for treatment of dry eye ➤ First patient dosed in Phase 3 trial investigating wet AMD treatment ➤ Acquisition and partnership news ➤ ASCRS news and events
Dry eye continues to be an important topic because of the many patients impacted and different ways it can present. Two cornea specialists highlighted some of the newer treatment options and how they are handling dry eye in their practice, including how they have updated their approach with experience.
➤ Topline Phase 3 results for sublingual, opioid-free sedation ➤ Phase 1 results for non-surgical cell therapy for corneal edema ➤ First Phase 2 study evaluates wet AMD gene therapy in both eyes of patients ➤ Update on Phase 3 study evaluating treatment for progressive myopia ➤ FDA to review NDA for first-in-class dry eye treatment ➤ Enrollment complete for Phase 1/2 study evaluating novel IOP-lowering drug delivery platform ➤ ASCRS news and events
➤ Positive topline Phase 3 confirmatory trial results for transepithelial crosslinking ➤ 18-month data from first-in-human drug-eluting IOL ➤ New Phase 2 findings for investigational geographic atrophy treatment ➤ Study: long-term, low-dose antiviral treatment reduces risk for HZO patients ➤ Acquisition news ➤ ASCRS news and events